-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s RG-6237
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6237 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s RG-6341
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6341 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6315 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6315 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6315 in Inflammation Drug Details: RG-6315 (RO-7303509) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6631 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6631 in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6631 in Ulcerative Colitis Drug Details: RG-6631 (RVT-3101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6457 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6457 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6457 in Solid Tumor Drug Details: RG-6457 (RO-7589831) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6468 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6468 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6468 in Solid Tumor Drug Details: RG-6468 (RO-7566802) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6341 in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6341 in Chronic Cough report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6341 in Chronic Cough Drug Details: RG-6341 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6538 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6538 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6538 in Relapsed Multiple Myeloma Drug Details: P-BCMA-ALL-O1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6538 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6538 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6538 in Refractory Multiple Myeloma Drug Details: P-BCMA-ALL-O1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6382 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6382 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6382 in Systemic Lupus Erythematosus Drug Details: RO-7507062 is under development...